4.8 Article

Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice

Journal

ONCOGENE
Volume 27, Issue 40, Pages 5354-5358

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2008.160

Keywords

von Hippel-Lindau (VHL) tumor suppressor; hypoxia-inducible factor (HIF); hemangioma; liver angiogenesis; mouse model; Cre-loxP recombination

Funding

  1. NIH [DK073467, CA100787]
  2. Center for Molecular Studies in Digestive and Liver Disease [P30-DK50306]
  3. Penn Diabetes and Endocrinology Research Center Functional Genomics Core [P30-DK19525]
  4. American Heart Association

Ask authors/readers for more resources

The von Hippel-Lindau tumor suppressor pVHL regulates the stability of hypoxia-inducible factors (HIF)-1 and-2, oxygen-sensitive basic helix-loop-helix transcription factors, which mediate the hypoxic induction of angiogenic growth factors such as vascular endothelial growth factor. Loss of pVHL function results in constitutive activation of HIF-1 and HIF-2 and is associated with the development of highly vascularized tumors in multiple organs. We have used a conditional gene-targeting approach to investigate the relative contributions of HIF-1 and HIF-2 to VHL-associated vascular tumorigenesis in a mouse model of liver hemangiomas. Here we demonstrate genetically that conditional inactivation of HIF-2 alpha suppressed the development of VHL-associated liver hemangiomas and that angiogenic gene expression in hepatocytes is predominantly regulated by HIF-2 and not by HIF-1. These findings suggest that HIF-2 is the dominant HIF in the pathogenesis of VHL-associated vascular tumors and that pharmacologic targeting of HIF-2 may be an effective strategy for their treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available